Chairman, Health and Global Policy Institute
Chairman, the Fukushima Nuclear Accident Independent Investigation Commission (NAIIC) by the National Diet of Japan (2011-12)
Chair and Representative Director, Global Health Innovative Technology Fund (2013-18)
Distinguished Research Affiliate, The MIT Media Lab (2011-2019)
Member of G8 World Dementia Council (2014-)
Chair of AI Advisory Board for COVID-19 (2020-)
Dr. Kurokawa received a MD degree in 1962 from the University of Tokyo, Faculty of Medicine. Following clinical training in internal medicine and then in nephrology at the Department of Medicine of the University of Tokyo Faculty of Medicine (62-69), he was a research associate, Department of Medicine, University of Pennsylvania School of Medicine (69-71), a senior research fellow at Cedars Sinai Medical Center and UCLA School of Medicine (71-73), assistant professor of Medicine, UCLA School of Medicine (73-74), associate professor of Medicine, Department of Medicine, Univ
Feb 19, 2021 10:05am Precision BioSciences treatment could offer an alternative to fighting heart disease with PCSK9-lowering drugs like Amgen’s Repatha as well as Sanofi and Regeneron’s Praluent, researchers said. (Pixabay)
Precision BioSciences was founded in 2006 to develop a genome editing technology that uses homing nucleases to make precise edits in DNA. Now, the company has preclinical evidence showing that the approach designed as a one-time treatment holds promise for treating familial hypercholesterolemia, high cholesterol that’s caused by abnormalities in the gene PCSK9.
A single dose of Precision’s treatment reduced the expression of PCSK9, resulting in a stable lowering of LDL cholesterol in nonhuman primates for three years, according to a study led by the University of Pennsylvania and published in the journal Molecular Therapy. The treatment reduced PCSK9 protein levels by 85% and LDL cholesterol levels by 56%.
The St Kitts Nevis Observer
New York City’s Department of Health and Mental Hygiene’s first chief medical officer, Haitian-born Dr. Michelle Morse
New York City’s Department of Health and Mental Hygiene (DOHMH) has appointed Haitian-born Dr. Michelle Morse to serve as the agency’s first chief medical officer (CMO).
“As the agency’s inaugural chief medical officer, Dr. Morse will have the responsibility of leading the agency’s work in bridging public health and health care, ensuring greater alignment and coordination with health care systems, and serving as a key liaison to clinicians and clinical leaders across New York City,” said the DOHMH in a statement on Tuesday.